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Background and Objectives
The chromosome 13 deletion (∆13) is one of the most frequent chromosomal alter-
ations in multiple myeloma (MM). ∆13 is associated with an unfavorable prognosis,
although there is increasing agreement that its prognostic relevance must be relat-
ed to the ploidy status and the presence of different chromosomal translocations.
The aim of this study was to provide a comprehensive analysis of the transcription-
al features of ∆13 in MM.
Design and Methods
Highly purified plasma cells from 80 newly diagnosed MM patients were character-
ized by means of fluorescence in situ hybridization (FISH) and high-density oligonu-
cleotide microarray for gene expression profiling and chromosomal alterations.
Results
We identified 67 differentially expressed genes in the patients with and without the
chromosome 13 deletion, all of which were downregulated in the cases with ∆13:
44 mapped along the whole chromosome 13, seven on chromosome 11 and three
on chromosome 19. Functional analyses of the selected genes indicated their
involvement in protein biosynthesis, ubiquitination and transcriptional regulation.
An integrative genomic approach based on regional analyses of the gene expres-
sion data identified distinct chromosomal regions whose global expression modu-
lation could differentiate ∆13-positive cases, in particular the upregulation of 1q21-
1q42 and the downregulation of 19p and almost the entire chromosome 11. FISH
analyses confirmed the close relationship between ∆13-positivity and the presence
of extra copies of 1q21-1q42 (p=6×10-4) or the absence of chromosome 11 and
19 trisomy (p=5×10-4).
Interpretation and Conclusions
Our results indicate that distinct types of chromosomal aberrations are closely
related to the transcriptional profiles of ∆13-positive cases, suggesting that the con-
tribution of ∆13 to the malignancy should be considered together with associated
abnormalities.
Key words: multiple myeloma, chromosome 13 deletion, gene
expression profiling, genome wide profiling, integrative genomics.
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ABSTRACT
Multiple myeloma (MM) is a fatal B-cell malig-nancy characterized by a heterogeneous clini-cal course and profound genomic instability.
Together with immunoglobulin-heavy chain (IGH)
translocations at 14q32, hyperdiploidy and chromo-
some 1q gain, chromosome 13 deletion (∆13) is one of
the most frequent chromosomal alterations: it has been
detected in 15-20% of patients by means of convention-
al karyotype analysis (an underestimate mainly due to
the limited mitotic activity of the neoplastic plasma
cells), and in as many as 50% of the patients by fluores-
cence in situ hybridization (FISH) analysis.1 The chromo-
some 13 abnormalities involve complete monosomy in
most MM patients;2,3 the minimal common deleted
region of approximately 350 Kb has been identified at
13q14 (1.5 Mb telomerically to the RB1 oncosuppressor
gene).4
Several authors have reported that chromosome 13
abnormalities indicate an unfavorable prognosis in
MM,5-8 and various studies have shown that chromo-
some 13 deletions are early events and represent an
adverse prognostic factor in the premalignant condition
of monoclonal gammopathies of undetermined signifi-
cance (MGUS).2,9,10 Shaughnessy et al.11 found that the
presence of ∆13 and other hypodiploid cytogenetic
abnormalities were associated with a poorer prognosis
in patients treated with intensive chemotherapy and
autologous bone marrow transplantation, and distin-
guished four groups of patients on the basis of com-
bined FISH, conventional cytogenetic and gene expres-
sion profiling analyses. However, despite recent
advances in identifying the transcriptional features of
subgroups of MM patients,12-17no comprehensive analy-
sis of the transcriptional profiles associated with ∆13 in
MM patients at diagnosis has been published.
The results of functional genomics studies suggest a
close relationship between genomic structural abnor-
malities (i.e. deletions or amplifications) and expression
imbalances, and have identified co-ordinated transcrip-
tional profiles of physically contiguous genes.18-20 In
addition, recent genotyping studies have found that
copy numbers have a considerable influence on gene
expression patterns, and have shown that organizing
gene-expression data by genomic mapping location and
scanning for regions containing statistically modulated
gene expression signals can lead to the detection of
chromosomal amplifications and deletions.21,22
Taken together, these considerations prompted us to
investigate the transcriptional profiles associated with
∆13 and develop a statistical model for identifying glob-
ally modulated chromosome regions associated with
∆13-positive or ∆13-negative patients.
Design and Methods
Patients and samples preparation
Bone marrow specimens from four normal donors
and pathological samples from 90 untreated MM
patients (51 males; median age 64 years, range 39-85; 50
described in previous reports)12,14,23were obtained during
standard diagnostic procedures after the subjects had
given their informed consent. Fifty-six patients had an
IgG protein monoclonal component, 18 IgA, two
IgG/IgA, and one IgD protein; 49 patients had the light
chain κ, and the κ/λ ratio was 1.3. The patients were
diagnosed and clinically staged according to previously
described criteria:24 30 patients were in stage IA, 34 in
stage IIA/B and 26 in stage IIIA/B. No conventional
cytogenetic (G-banding) analyses were available.
Plasma cells were purified from the bone marrow
samples using CD138 immunomagnetic microbeads
(MidiMACS® system, Miltenyi Biotec, Auburn, CA,
USA) as previously described.14,23 The purity of the
selected plasma cell populations was assessed by means
of morphology and flow cytometry, and was > 90% in
all cases.
Gene expression profiling
Total RNA was extracted and purified, and biotin-
labeled cRNA was synthesized as previously
described.14 In accordance with the Affymetrix proto-
cols, 15 µg of fragmented cRNA were hybridized on
HG-U133A Probe Arrays (Affymetrix Inc., Santa Clara,
CA, USA), and the oligonucleotide arrays were scanned
using an Agilent GeneArray Scanner G2500A (Agilent
Technologies, Waldbronn, Germany). The quality
reports for the scanned arrays were as follows; scaling
factor: median 1.066, range 0.468-2.459; percentage of
present genes: median 38.85, range 27.7-46.5; 3’/5’ actin
ratio: median 1.23, range: 0.83-2.27; 3’/5’ GAPDH ratio:
median 1.075, range 0.75-2.40.
Microarray data analysis
The probe level data were converted to expression
values using the Bioconductor function for the robust
multi-array average (RMA) procedure,25 in which per-
fect match intensities are background adjusted, quantile-
quantile normalized, and log2-transformed. The detection
calls were calculated using the default parameters of the
Affymetrix MAS 5.0 software package. Data with
absent calls in all of the arrays were filtered out; no fil-
tering procedure was applied to the intensity levels. The
overexpression of CCND1, CCND2 and CCND3 genes
was calculated as previously described.12 Unsupervised
analyses were applied to a subset of genes whose aver-
age change in expression levels varied at least 2-fold
from the mean across the whole panel. In order to per-
form the hierarchical agglomerative clustering of the
selected probe lists, Pearson’s correlation coefficient and
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average-linkage were used as distance and linkage
methods in DNA-Chip Analyzer (dChip) software,26,27 as
previously described.14
The differentially expressed genes discriminating ∆13-
positive and ∆13-negative classes were identified using sig-
nificant analysis of microarrays (SAM) software (Excel
front-end publicly available at http://www-stat.stanford.
edu/~tibs/SAM/index.html).28 The cut-off for significance
was determined by tuning the ∆ parameter on the false
discovery rate (median FDR=0% and 90th percentile
FDR=0%) and controlling the q-value for the gene list.
The selected probe list was visualized by means of dChip
software. The chromosomal regions with modulated
gene expression signals were identified using a non-para-
metric model-free statistical method called locally adap-
tive statistical procedure (LAP).29 For the purposes of this
study, the intensity levels were generated from CEL files
using RMA and, after annotation, the probe sets without
any chromosomal location information were filtered out,
as were those on chromosomes X and Y. The differential
expressions between the ∆13-positive and ∆13-negative
groups were calculated using the regularized t-statistic di
and led to 11613 unique ID. The null statistic was defined
by means of 100000 permutations of the statistic values di
(i.e. by randomly assigning the scores to the 11613 loci)
and then, for each permutation, smoothed over the chro-
mosomal coordinate. Finally, differentially expressed
chromosomal regions were identified using the q-value
calculated from the distribution of empirical p-values.
The data discussed in this article have been deposited
in National Center for Biotechnology Information’s
Gene expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo) and are accessible
through GEO Series, accession number GSE6365.
Real-time quantitative polymerase chain reaction
(RT-Q-PCR)
One microgram of total cellular RNA from purified
plasma cell populations was reverse transcribed to
cDNA using random hexamer primers. RT-Q-PCR was
performed in triplicate using an ABI PRISM 7700
Sequence Detector (Perkin Elmer, Foster City, CA,
USA). The results were expressed using the compara-
tive Ct method (2-∆∆Ct), according to manufacturer’s
manual (Applied Biosystems. Relative Quantification of
Gene Expression. ABI PRISM 7700 Sequence Detection
Systems. User Bulletin #2, PE Applied Biosystems,
1997). The average Ct value for RB1 was normalized
with respect to the average Ct value for GAPDH in
order to yield the ∆Ct. The ∆Ct value obtained from
JJN3 human myeloma cell line (chosen as the calibrator)
was then subtracted from the average ∆Ct value for
each patient, to obtain ∆∆Ct. Human RB1 and endoge-
nous controlGAPDHwere analyzed using, respectively,
assay on-demand and pre-developed assay reagents
(PDAR, Applied Biosystems, Foster, CA, USA).
Fluorescence in situ hybridization (FISH)
The FISH procedure and specific probes for the detec-
tion of IGH translocations, the 13q14 deletion and chro-
mosome 11 polysomy have been previously
described.12,23 Additional copies of chromosome 19 were
investigated using two BAC clones located ~2 Mb from
the pericentromeric regions 19q13.11 (CTD-2632B17)
and 19p13.11 (CTD-3149D2). The gain of 1q21 and
1q42 regions was analyzed by means of two BAC
clones covering the BCL9 gene (CTD-2555I11) and
ARF1 gene (RP11-155G12), which map, respectively, to
1q21.1 and 1q42.13. Hyperdiploid status was deter-
mined according to the criteria recently proposed by a
major investigational group in MM,30 based on the FISH
investigation of chromosomes 5, 9 and 15. The follow-
ing probes were used: the 9 and 15 α satellite probes
(kindly provided by M. Rocchi, University of Bari, Italy) and
a specific selected BAC probe (CTD-2530B8) containing
the STS marker D5S630 mapping at 5p15.31. Two co-
hybridizations steps were performed in each case. All
of the clones were selected by browsing the UCSC
Genome Database (http://genome.ucsc.edu/).
Results
Correlation between ∆13 status and the main
genetic lesions in MM
Eighty of the 90 samples included in our microarray
database were characterized by FISH for the presence of
the chromosome 13q14 deletion leading to the identifi-
cation of 43 (53.8%) positive patients. The correlations
with the main chromosomal aberrations associated
with MM are shown in Table 1. Hyperdiploidy was
observed in 28 (43%) of the 65 tumors for which mate-
rial for FISH was available: 12 out of 36 ∆13-positive
patients and 16 out of 29 ∆13-negative patients. Although
we found a similar frequency to that reported in the lit-
erature31 and identified a greater prevalence of hyper-
diploid patients in the ∆13-negative group, our data did
not show a statistically significant correlation between
∆13-positive cases and ploidy status, as had been previ-
ously reported.30,32 Chromosome 1q amplification was
identified by FISH in 37 (53%) of 70 patients for whom
material was available; the close correlation between
∆13-positivity and additional chromosome 1 material
(28/39 vs 9/31 patients; p=6×10-4) indicated that the 1q
gains can be considered specifically associated with ∆13-
positivity (see below).
Finally, the 80 patients investigated for ∆13 status were
stratified according to the recently proposed transloca-
tion/cyclin D (TC) molecular classification, which takes
into account the presence of the main IGH chromoso-
mal translocations and the expression of cyclin D genes,
whose deregulation represents a common event in MM.
Following the criteria reported by Hideshima et al. and
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Table 1. Molecular characterization of the ∆13-positive and ∆13-negative patients.
∆13-positive samples ∆13-negative samples
Patients TC HD +11 +19 +1q21 Patients TC HD +11 +19 +1q21
+1q42 +1q42
MM-019 1 − + − + MM-015 1 − + + +
MM-037 1 − − − − MM-026 1 nd − − −
MM-052 1 − − + + MM-031 1 − + + +
MM-070 1 − − − − MM-032 1 − + − −
MM-100 1 − − − − MM-054 1 nd + nd nd
MM-115 1 − + − + MM-055 1 − − − −
MM-159 1 − + − − MM-111 1 − − − −
MM-038 2 nd − + − MM-119 1 nd − nd nd
MM-027 3 + − + + MM-126 1 nd + nd nd
MM-036 3 − + − + MM-128 1 − + − −
MM-040 3 + − + + MM-140 1 − − − −
MM-047 3 + − + + MM-014 2 + + + −
MM-048 3 + + + + MM-030 2 + + + −
MM-072 3 nd − − + MM-034 2 + − + −
MM-078 3 − + + − MM-035 2 nd + + −
MM-082 3 + − + + MM-039 2 + + + −
MM-094 3 − − − + MM-043 2 − + + +
MM-101 3 nd + nd nd MM-049 2 + + + −
MM-103 3 nd + + nd MM-056 2 nd + nd nd
MM-107 3 nd − + nd MM-077 2 + + + −
MM-114 3 + − + + MM-079 2 + + + −
MM-117 3 − − + − MM-121 2 + + + −
MM-129 3 + − + + MM-131 2 − + + −
MM-160 3 + nd + − MM-143 2 + + + −
MM-161 3 + − + + MM-146 2 + − + +
MM-167 3 − − − + MM-151 2 + + + −
MM-021 4 − − − + MM-152 2 + + + −
MM-042 4 + − + + MM-016 3 + + + +
MM-063 4 nd − − − MM-050 3 nd − nd nd
MM-067 4 − − − + MM-092 3 − − + +
MM-074 4 + − + + MM-106 3 − − + −
MM-083 4 − − − + MM-148 3 + − + +
MM-087 4 − − − + MM-149 3 + + + −
MM-089 4 nd − − nd MM-150 3 + − + +
MM-104 4 − − − + MM-153 3 − + + +
MM-109 4 − − − − MM-066 4 − − − −
MM-113 4 + − − − MM-004 5 nd nd nd nd
MM-123 4 − − + +
MM-133 4 − − − +
MM-158 4 − − − +
MM-025 5 − + + +
MM-069 5 − + + +
MM-154 5 − − − +
nd: not determined; TC: translocation/cyclin classification; HD: hyperdiploidy.
Figure 1. Unsupervised analysis of the samples from the 90 MM patients. Unsupervised analysis of gene expression profiles in purified
CD138+ plasma cell samples from 90 MM cases. The dendrogram was generated using a hierarchical clustering algorithm based on the
average-linkage method and Pearson’s correlation. The samples are grouped on the basis of the expression levels of the 546 most vari-
able genes. Information about chromosome 13 deletion (+=presence of ∆13; n=data not available) and TC classes is included alongside
the MM patients’ progressive numbers.
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recently investigated by us,12,33 the patients were strati-
fied in five groups: TC1, characterized by the t(11;14) or
t(6;14) translocation, with consequent overexpression of
CCND1 or CCND3, and a non-hyperdiploid status;
TC2, showing low to moderate levels of the CCND1
gene in the absence of any primary IGH translocation,
and a hyperdiploid status; TC3, including tumors that
do not fall into any of the other groups, most of which
expressed CCND2; TC4, showing high CCND2 levels
and the presence of the t(4;14) translocation; and TC5,
expressing the highest levels of CCND2 in association
with either the t(14;16) or t(14;20) translocation. It is
worth noting that 16 out of 17 TC2 patients did not
show any chromosome 13 abnormalities (94%, p<10-4),
whereas 14 out of 15 TC4 patients, who had the t(4;14)
translocation, were included in the ∆13-positive group
(93%, p<10-4) (Table 1). These data confirm our previous
observations concerning the distribution of ∆13-positivi-
ty within TC classes.12
∆13-positive patients showed downregulation of genes
mainly located on chromosome 13
An unsupervised analysis using the hierarchical clus-
tering algorithm was made in order to determine
whether the clustering of the gene expression profiles of
the MM samples was associated with the presence of
∆13. The 90 MM cases described by the 546 most vari-
able genes throughout the database (i.e. genes with at
least a two-fold average change in expression from the
mean across the whole panel), generated the dendro-
gram shown in Figure 1. The clustering algorithm split
the samples into two major groups of 49 and 41 speci-
mens, with the first containing 26/43 ∆13-positive
patients (60%, p=5.9×10-4) and the second 27/37 ∆13-neg-
ative patients (73%, p=2.9×10-4). However, despite the
significant correlation of the two major subgroups with
the prevalence of ∆13, the dendrogram was mainly driv-
en by the presence of the principal IGH translocations
and TC stratification, as previously described.12,14
Using SAM on the 80 samples for which FISH ∆13 char-
acterization was available, we performed a supervised
analysis in order to identify the transcriptional finger-
prints characterizing ∆13-positive and ∆13-negative
groups, and found 87 differentially expressed transcripts
(specific for 67 genes), all of which were downregulated
in the ∆13-positive group (Figure 2): in particular, 44 were
localized along the whole chromosome 13 (evenly dis-
tributed from 13q11 to 13q34), seven on chromosome
11, and three on chromosome 19 and 14q (see
Supplemental data 1 for the complete list). The selected
genes included a relatively large class of transcripts
involved in protein biosynthesis encoding for ribosomal
protein related to large (L21, L22, L24, L31, L36a, LP2)
and small ribosome subunits (S2, S29, and the mitochon-
drial S31), together with EIF3S7, FAU and DHPS genes
involved in translational machinery; notably, only two
of these (L21 and S31) mapped to chromosome 13q. We
also identified genes involved in transcription regulation
(SAP18, POLR1D, GTF3A, ELF1, GTF2F2, MED4,
PHF11, MYCBP2), DNA repair (PARP4, HMGB1, PSCP1,
ERCC5), chromatin assembly and cell-cycle (HSMPP8,
RFP2, CDC16, CUL4A), ubiquitin-dependent protein
catabolism (RNF6, C13orf22, UCHL3), protein transport
(DNAJC15, KPNA3, RANBP5), signaling (FNBP4,
AKAP11, STK24, ARHGEF7, GMFG), cytoskeleton com-
ponents (TUBGCP3, PDLIM1), and RNA metabolism
(NUFIP1, METTL3). In particular, we identified the pres-
ence of the putative tumor suppressor genes RFP2 and
RNF6 (mapping to 13q14.3 and q12.2, respectively), and
GLTSCR2, located at 19q13.3. The supervised analysis
did not identify the RB1 tumor suppressor gene located
at 13q14.2 as being differentially expressed between ∆13-
positive and ∆13-negative cases, although a downregula-
tion (average 1.8- fold change) was observed in del13-pos-
itive (data not shown). However, the transcript could be
identified in a SAM analysis made under less stringent
conditions (FDR <1%) of those with a higher q-value
(0.4711, over the 280thposition in the list; data not shown).
RB1 expression levels were validated by means of a RT-
Q-PCR analysis in a panel containing 15 ∆13-positive and
14 ∆13-negative samples from our dataset; this analysis
showed a significant downregulation of RB1 transcript in
the ∆13-positive patients (p=4.205×10-4 in a Wilcoxon’s
exact rank test; Figure 3).
Transcriptional regional analysis identified globally
modulated regions in ∆13-positive patients
The gene expression data from the ∆13-positive and
∆13-negative samples were also analyzed with respect to
the physical localization of the genes in the genome in
order to verify whether the deletion of chromosome 13
is reflected in chromosomal regions with transcription-
al imbalances. To assess the correspondence between
the differentially expressed chromosomal regions and
∆13-positivity, the gene expression signals were analyzed
using a non-parametric model-free statistical method
(LAP). The LAP procedure allowed the identification (at
a q-value=0) of 1063 differentially expressed genes
located on chromosomes 1, 3, 11, 13, 14, and 19 (Figure
4). It is worth noting that almost the entire chromosome
13 was globally downregulated in the ∆13-positive
group. Additionally, downregulation was observed in
the regions 19p13.3-p13.2 (absolute positions: 447,489-
10,689,754 base pairs), 14q24.1-q24.3 (69,862,537-
72,672,931 bp), 3p22.3-p21.1 (35,696,119-47,032,925
bp), 11p15.5-p15.3 (192,923-10,830,920 bp), 11q12.2-
q14.3 (60,414,779-93,157,095 bp) and 11q22.3-q23.3
(102,318,933-117,735,511 bp). Finally, the LAP analysis
revealed upregulation of chromosome 1 regions span-
ning 1q21-q22 and 1q31.3-q42.3 (155,393,568-
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237,264,911 bp).
FISH analyses revealed a correlation of gene
expression levels and chromosome copy number in
∆13-positive and ∆13-negative patients
Following the identification of globally modulated
regions in ∆13-positive tumors, FISH analyses were made
in order to correlate the transcriptional profiles with their
respective chromosome copy number in ∆13-positive and
∆13-negative patients. Chromosomes 1, 11 and 19 were
investigated (Table 1), and extra copies of chromosome 11
were found in 33 (42%) of the 78 patients for whom
Figure 2. Supervised analysis of samples from ∆13-positive vs ∆13-negative MM patients. Expression profiles of the 80 MM samples (∆13
status assessed by FISH) for the 87 probe sets selected by SAM analysis. The color scale bar represents the relative gene expression
changes normalized by the standard deviation. Information about chromosome 13 deletion and TC class stratification is included along-
side the MM patients’ progressive numbers.
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material was available. There was a close correlation
(p=5×10-4) between ∆13-positivity and the absence of
additional copies of chromosome 11, as well as a valid
correlation (p=0.015) between ∆13-positivity and the
absence of extra copies of chromosome 19, which was
found in 44 (60%) of the 73 patients for whom materi-
al was available. Finally, the two well-defined regions of
chromosome 1q identified as upregulated by chromoso-
mal regional analysis were analyzed using locus-specif-
ic probes and showed extra signals of both the 1q21 and
1q42 regions in 37 (53%) of 70 cases analyzed; a differ-
ent number of extra copies was detected in only three
cases (MM-069, MM-016 and MM-148). The results
revealed a close correlation between ∆13-positivity and
additional chromosome 1 material (28/39 patients vs
9/31 patients; p=6×10-4), thus indicating that the extra
copies of 1q21 and 1q42 regions can be considered
specifically associated with ∆13-positivity in MM.
Discussion
Although ∆13 has frequently been identified as a hall-
mark in MM, many aspects concerning its biological con-
sequences remain to be investigated; in particular, there is
still a need for a comprehensive transcriptional analysis of
∆13 in MM patients at diagnosis. The aim of this study
was to provide new insights into the molecular character-
ization of ∆13 in MM.
Our results confirm that ∆13 is rarely observed as a sole
genetic abnormality in MM, a finding that had already
suggested that the negative prognostic value of ∆13 should
not be considered per se but in relation to its frequent
association with other adverse prognostic factors, such as
non-hyperdiploidy or the presence of t(4;14) and
t(14;16)/t(14;20) chromosomal translocations.34,35 Our
analyses support this argument by showing that the clus-
tering based on transcriptional profiling of MM samples
was driven more by the distribution of the TC groups
than by the presence of ∆13. They also further extend the
evidence that ∆13 is randomly distributed among TC1 and
TC3 patients, absent in TC2 patients, and strictly associ-
ated with patients in groups TC4 and TC5.12 Moreover,
an overall survival analysis of the patients in our dataset
did not reveal any significant difference between ∆13-pos-
itive and ∆13-negative groups, although the relatively small
number of cases, the treatment heterogeneity and the
rather short follow-up do not allow any definite conclu-
sions to be drawn (Supplemental data 2).
Previous data on the expression profiles associated with
∆13 are quite limited. Shaughnessy et al.11 reported the
results of a supervised analysis of ∆13-positive versus ∆13-
negative patients in the context of patient stratification
based on the presence/absence of cytogenetic alterations,
and in relation to high-dose conventional therapy fol-
lowed by autologous bone marrow transplantation. They
found 35 differentially expressed genes, 32 of which
(including RB1) mapped to chromosome 13, with only
one (IGFR1 localized on chromosome 12q) being upregu-
lated in ∆13-positive patients. Our conventional supervised
analyses on MM patients at diagnosis were made using
stringent criteria and confirmed that ∆13-positivity leads to
greater haploinsufficiency of specific chromosome 13
genes, as 44 of the 67 downregulated genes were local-
ized on chromosome 13. It is worth noting that function-
al genomic annotation analyses of the selected genes indi-
cate that these play important roles in basic cell biological
processes. We identified RFP2 and RFN6, which encode
for RING finger proteins, as putative tumor suppressor
genes located on chromosome 13. RFP2 (also known as
LEU5) maps within the minimally 13q deleted region
close to D13S272, and shares significant homology with
the BRCA1 tumor suppressor gene;36 RFN6maps to 13q12
and has been found to be deleted and mutated in
esophageal squamous cell carcinomas. A third putative
tumor suppressor gene, GLTSCR, localized on 19q13.3
and involved in the phosphorylation and stability of the
tumor suppressor gene PTEN, is frequently associated
with allelic loss in human diffuse gliomas. It is worth not-
ing that the previously described RFP2, together with five
of the other genes included in our list (C13orf23, MRPS31,
AKAP11, GTF2F2 and NUDT15), have recently been
described by Carrasco et al.37 as candidate genes at 13q14
showing significantly reduced expression in a subgroup of
MM patients with ∆13, as assessed by array comparative
genomic hybridization analyses.
As regards the putative tumor suppressor gene RB1, the
published gene expression data are rather controversial:
the earlier observation by Shaughnessy et al.,11 showing
RB1 as a gene discriminating ∆13-positive from ∆13-nega-
tive patients has not been confirmed by more recent stud-
ies.37,38 In our panel, RB1 was not identified as downregu-
Figure 3. RT-Q-PCR analysis of RB1. Box plot of RB1 mRNA
expression levels obtained by means of RT-Q-PCR analysis in
∆13–negative and ∆13–positive patients.
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lated in ∆13-positivepatients when the stringent criteria of
SAM analysis were applied; however, differential expres-
sion was observed if the supervised analysis was per-
formed using less stringent criteria, and was further sup-
ported by RT-Q-PCR validation of a subset of patients.
The most likely explanation is the variability of RB1
expression level (i.e. high variance) within ∆13-positiveand
∆13-negativegroups, as indicated by both the gene expres-
sion and RT-Q-PCR data.
A large proportion of the downregulated transcripts in
∆13-positive patients, which were mainly localized on
chromosome 13, encode for proteins involved in the neg-
ative control of cell proliferation and the cell cycle. For
example, SAP18 encodes for a protein that interacts with
SIN3, a component of histone-deacetylase complexes,
and enhances SIN3-mediated transcriptional repression,39
and APRIN (also known as AS3) is implicated in negative
cell cycle regulation by androgens in epithelial cells.40
Furthermore, the product of the CDC16 gene is a member
of the anaphase-promoting complex, which functions as
a protein ubiquitin ligase that regulates the mitotic cyclin
degradation system governing the exit from mitosis. It
has also been shown that inactivation of the CUL4A gene,
which is involved in a similar pathway, causes massive
DNA re-replication in C. elegans, most probably due to
failed degradation of replication-licensing factors.41
Interestingly, together with CDC16 and CUL4A, many
other genes encoding proteins involved in ubiquitin-
dependent catabolism, such as the putative tumor sup-
pressor genes RNF6 and RFP2 described above, and the
C13orf22, UCHL3, MYCBP2 and TPP2 genes, seem to be
downregulated in ∆13-positive patients. Proteolysis via the
ubiquitin system plays an important role in a variety of
basic cell processes, such as cell cycle regulation, growth
and differentiation. Ubiquitin-mediated protein degrada-
tion involves the conjugation of multiple moieties of
ubiquitin to the protein, and the degradation of the con-
jugated protein by the 26S proteasome complex. Because
of the large pleiotropic spectrum of protein substrates, the
ubiquitin-proteasome pathway has been implicated in
the pathogenesis of a number of diseases, including can-
cer. In recent years, new and selective proteasome
inhibitors have been employed as anti-tumor agents, par-
ticularly in MM.42 In addition, various down-regulated
genes in ∆13-positive patients (all located on 13q) are
involved in DNA repair mechanisms (PARP4, HMGB1,
PSPC1, ERCC5), and their defects are associated with a
variety of human cancers. This finding strongly suggests
that haploinsufficiency of the proteins encoded by these
genes may play a role in the genomic instability and more
adverse outcomes of ∆13-positivepatients.
A significant fraction of genes downregulated in ∆13-
positive patients encode for molecules involved in the
biosynthesis of mainly ribosomal and translational-asso-
ciated proteins, but only two of the 11 genes involved in
this pathway are located on chromosome 13q. We have
previously reported that the highly co-ordinated expres-
sion of genes involved in the translational machinery,
mainly located on chromosome 19, is a distinctive feature
of MM patients belonging to the TC2 group,12 who show
an almost complete association with gains in chromo-
some 11 and 19 (Table 1). The presence of TC2 patients
in the ∆13-positive group, and the highly significant
inverse correlation between the presence of ∆13 and the
presence of extra copies of chromosome 11 and 19 may,
therefore, account for the relative downregulation of the
genes involved in protein biosynthesis in ∆13-positive
patients.
As it is known that chromosomes 11 and 19 are associ-
ated with hyperdiploidy in MM, and previous findings
indicate that ∆13 is associated with non-hyperdiploid
tumors,34 it can be argued that the transcriptional profiles
observed in ∆13-positive patients may be partially related
to the ploidy status. However, we did not find a signifi-
cant correlation between ∆13-positivity and non-hyper-
diploidy, or the downregulation of genes or modulated
regions located on other chromosomes involved in hyper-
diploidy (such 5, 9 and 15). These findings are in accor-
Figure 4. Regional analysis of samples
from ∆13-positive vs ∆13-negative patients.
Whole genome plot of the differentially
expressed regions at q-value=0 in the ∆13-
positive and ∆13-negative patients. The ver-
tical axis represents the progressive chro-
mosome number; the horizontal axis (blue
lines) shows the progressive absolute posi-
tion of the probes represented on the HG-
U133A array for each chromosome. The
white bars indicate the exact chromosomal
locations, and the colored perpendicular
lines the locations and up- (red) or down-
regulation (green) of the 1063 differential-
ly expressed genes in ∆13-positive patients
(see geneplotter package from
Bioconductor for details).
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dance with the observations of a recent study showing
that ∆13-positivity is associated with a fraction of hyper-
diploid tumors.37 Overall, it may be suggested that the
transcriptional profile of ∆13-positive cases is not directly
related to the ploidy status, despite the higher prevalence
of TC2 within ∆13-negative patients and/or TC4 or TC5
translocations within ∆13-positive patients.
One important finding of our study is the strong asso-
ciation between ∆13MM patients and extra copies of chro-
mosome 1q, in particular of the 1q21 and 1q42 regions.
The association with 1q21 gain, determined by conven-
tional cytogenetics, had been previously described by
Nakagawa et al.,43 although the number of cases was too
few to define a significant correlation between the two
aberrations. More recently, a significant association was
reported by Gutierrez et al., who used comparative
genomic hybridization in a larger panel of cases.44 As dis-
cussed above, the chromosome 1q gain, together with ∆13-
positivity, has recently been considered a discriminating
molecular feature of hyperdiploid patients with a shorter
survival.37 Our study extends this finding by identifying a
significant correlation between 1q21 and 1q42 regions
and ∆13 using FISH and integrative genomic approaches. In
particular, the application of the novel LAP algorithm to
our series revealed the presence of globally upregulated
expression levels for the genes residing at 1q21-1q42 in
∆13-positive patients. It is worth noting that, when the
transcriptional profiles of ∆13-positive and ∆13-negative
patients were compared with an albeit limited number of
four normal donors by means of the LAP algorithm, the
results suggested that the upregulation of the 1q regions
(absolute position: 162,332,107-229,426,616 bp) could be
considered as being specific to the ∆13-positive group, as
well as the expected downregulation of most of chromo-
some 13, whereas the analysis did not provide any evi-
dence of modulated expression on chromosomes 11 and
19 distinguishing ∆13-positive and ∆13-negative groups
(data not shown). The fact that none of the genes found to
be differentially expressed in our ∆13-positive and ∆13-neg-
ative samples was located on the 1q arm should be con-
sidered in the light of the stringent criteria applied in the
supervised analysis (FDR=0%) because, when less strin-
gent criteria were applied (FDR<15%, 2164 transcripts),
an appreciable fraction of upregulated genes located on 1q
arm (about 6 %) were identified in ∆13-positive patients
(data not shown).
One intriguing aspect of ∆13 in MM is the possible
involvement of microRNA localized in this chromosome.
MicroRNA represent a growing class of small non-coding
RNA that are thought to regulate gene expression; the
loss or amplification of microRNA has been reported in a
large variety of tumors and may affect normal cell growth
and proliferation. Interestingly, two microRNA are delet-
ed and downregulated in B-cell chronic lymphocytic
leukemia with deletion and translocations at 13q14.
Furthermore, it has been reported that microRNA profiles
can be useful to distinguish B-cell chronic lymphocytic
leukemias with different clinical outcomes.45 Future inves-
tigation of microRNA profiles in MMmay provide impor-
tant and novel contributions to the understanding of the
mechanisms of myelomagenesis.
In conclusion, our findings indicate that the transcrip-
tional differences between ∆13-positive and ∆13-negative
patients mainly involve genes located on chromosome 13,
thus suggesting the existence of a strict correlation
between transcriptional features and chromosomal alter-
ations. Our data also show that the impact of ∆13 on the
neoplastic phenotype should be considered together with
concomitant abnormalities, such as the gain of chromo-
some 1q21-q42 region.
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